Two Biotech Stocks with Major Catalysts


 
 
05:41 04/03/2019

Biotech stocks with major US FDA dates approaching can offer sizable opportunities, especially if their treatments show signs of success.

Here are two stocks with major catalysts nearing.

Biotech Stock No. 1 -- Nabriva Therapeutics NBRV 

At the moment, the stock is consolidating with heavy volume.  As we near June 30, 2019, we believe the stock could push significantly higher. That’s when the FDA will rule on its Contepo IV drug for the treatment of complicated urinary tract infections.  If approved, it will be a first-in-class intravenous (IV) antibiotic with broad spectrum activity against Gram-negative and Gram-positive organisms, including ESBL-producing Enterobacteriaceae and other multi-drug resistant organisms. Annually, some three million cases of cUTIs require hospital treatment in the U.S. for Gram-negative infections. 

 

Biotech Stock No. 2 -- Heron Therapeutics HRTX 

 

The stock is just beginning to accelerate higher, as we near the FDA’s April 30, 2019 decision on HTX-011 for the management of post-operative pain.  In studies, patients injected with HTX-011 reported significantly less pain intensity than those given bupivacaine.  It also has proof that shows that patients given HTX-011 were less likely to require opioid rescue medications.




This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read